Interim trial findings suggest osteopathic manipulative treatment is feasible and well-tolerated in infants with positional plagiocephaly.
Publication|Articles|March 5, 2024
Free Continuing Education Credits
Advertisement
Registration is now open for the next “Current Issues in Vaccines” webinar. Scheduled for April 3, 2024, at noon ET, Dr. Paul Offit will discuss:
- Covid-19 Vaccine Myths: And the Hits Just Keep on Comin’
The “Current Issues in Vaccines” series is supported by the Thomas F. McNair Scott Endowed Research and Lectureship Fund and co-sponsored in collaboration with the Pennsylvania chapter of the American Academy of Pediatrics and Nesbitt School of Pharmacy at Wilkes University. Registration is available here: https://event.webcasts.com/starthere.jsp?ei=1657748&tp_key=513c9db34d
Advertisement
Related to this article
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
A teddy bear program pairs children with stuffed animals that have matching medical devices to help normalize care and reduce device-related anxiety.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
More than half of firearm-owning parents of children aged 1 to 5 years reported at least 1 firearm stored unlocked, loaded, or both.
The Autus Size-Adjustable Valve can be implanted at about 13 mm and balloon-expanded to 22 mm as children grow, with no deaths or strokes among 62 patients studied.
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
AAP’s 2026 conference will bring pediatricians updates on AI, vaccines, misinformation, nutrition, mental health, and clinical care.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves expandable Autus valve for congenital pulmonary valve disease
2
BLA submitted to FDA for Viaskin peanut patch in children aged 4 to 7 years with peanut allergy
3
FDA news in pediatrics: September 2026
4
What to expect at the AAP 2026 National Conference & Exhibition
5